IRF4 down-regulation via IRF4 antisense oligonucleotide (ASO) ION251 reduced tumor formation and myeloma dissemination, eradicated myeloma progenitors and improved survival and sensitivity to myeloma drugs [40]. The gene discussed is IRF4; the disease is plasma cell myeloma.